A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck
dc.contributor.author | Eckenrode, John L. | en_US |
dc.contributor.author | Wheeler, Richard H. | en_US |
dc.contributor.author | Forastiere, Arlene A. | en_US |
dc.date.accessioned | 2006-09-11T15:53:28Z | |
dc.date.available | 2006-09-11T15:53:28Z | |
dc.date.issued | 1985-12 | en_US |
dc.identifier.citation | Eckenrode, John L.; Wheeler, Richard H.; Forastiere, Arlene A.; (1985). "A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck." Investigational New Drugs 3(4): 389-392. <http://hdl.handle.net/2027.42/45289> | en_US |
dc.identifier.issn | 0167-6997 | en_US |
dc.identifier.issn | 1573-0646 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45289 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3866756&dopt=citation | en_US |
dc.description.abstract | Sixteen patients with advanced squamous cell carcinoma of the head and neck were entered into a phase II trial of Aclacinomycin-A (ACM), 100 mg/M 2 administered by brief infusion every three weeks. All patients had received prior radiation therapy and prior non-anthracycline containing chemotherapy. No clinically significant disease regression was observed in fourteen patients having adequate trials. The major toxicity was myelosuppression; leukopenia occurred in 93% of patients. Gastro-intestinal toxicity was mild and included two patients with transient liver function test abnormalities. No antitumor activity was observed in this patient population which was heavily pre-treated and had a median Karnofsky performance status of only 60%. The results of other phase II trials of ACM-A have been similarly disappointing suggesting that it is not a clinically useful agent in the treatment of solid tumors. | en_US |
dc.format.extent | 259632 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Martinus Nijhoff Publishers ; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Phase II Trial | en_US |
dc.subject.other | Aclacinomycin-A | en_US |
dc.subject.other | Aclarubicin | en_US |
dc.subject.other | Head and Neck Cancer | en_US |
dc.title | A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Hematology/Oncology University of Michigan Hospital, 48109, Ann Arbor, MI; Oncology Section, Veterans Administration Medical Center, 48105, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Hematology/Oncology University of Michigan Hospital, 48109, Ann Arbor, MI; Comprehensive Cancer Center, University of Alabama in Birmingham, University Station, Birmingham, Alabama | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Hematology/Oncology University of Michigan Hospital, 48109, Ann Arbor, MI; Oncology Section, Veterans Administration Medical Center, 48105, Ann Arbor, Michigan; Oncology Section, VA Medical Center, 2215 Fuller Rd., 48105, Ann Arbor, MI | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 3866756 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45289/1/10637_2004_Article_BF00170763.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00170763 | en_US |
dc.identifier.source | Investigational New Drugs | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.